Docetaxel as a vital option for corticosteroid-refractory prostate cancer

International Urology and Nephrology

Volumn 43, Issue 4, 2011, Pages 1081-1087

  Kume, Haruki ^a   Suzuki, Motofumi ^a   Fujimura, Tetsuya ^a   Fukuhara, Hiroshi ^a   Enomoto, Yutaka ^a   Nishimatsu, Hiroaki ^a   Ishikawa, Akira ^a   Homma, Yukio ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Castration refractory prostate cancer; Corticosteroid refractory; Dexamethasone; Docetaxel

Indexed keywords

ALKALINE PHOSPHATASE; DEXAMETHASONE; DOCETAXEL; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAXOID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; CANCER STAGING; CONTROLLED STUDY; CORTICOSTEROID REFRACTORY PROSTATE CANCER; DISEASE SEVERITY; DRUG EFFICACY; FUNCTIONAL STATUS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; ADENOCARCINOMA; ARTICLE; BLOOD; DRUG RESISTANCE; KARNOFSKY PERFORMANCE STATUS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; HUMANS; KARNOFSKY PERFORMANCE STATUS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84859932226     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-9922-0     Document Type: Review

References (17)

1. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA (2004) Eisenberger MA; TAX 327 Inves-tigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
4. Takenaka A, Yamada Y, Kurahashi T, Soga H, Miyake H, Fujisawa M (2008) Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients. Int J Urol 15:106-109
5. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson R (1995) L.: Prostate specific antigen levels and clinical response to low dose dexamethasone for hor-mone-refractory metastatic prostate carcinoma. Cancer 76:96-100
6. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Bellde-grun AS (2006) Secondary hormonal therapy for advanced prostate cancer. J Urol 175:27-34
7. Dowsett M, Shearer RJ, Ponder BA, Malone P, Jeffcoate SL (1988) The effects of aminoglutethimide and hydro-cortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients. Br J Cancer 57: 190-192
8. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic pros-tatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597
9. Saika T, Kusaka N, Tsushima T, Yamato T, Ohashi T, Suyama B, Arata R, Nasu Y (2001) Kumon H; Okayama Urological Cancer Collaborating Group. Treatment of androgen-independent prostate cancer with dexametha-sone: a prospective study in stage D2 patients. Int J Urol 8:290-294
10. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Ei-senberger M (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18:1440-1450
11. Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, Akaza H (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38:365-372
12. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M (1995) Mediation of glu-cocorticoid receptor function by transforming growth fac-tor beta I expression in human PC-3 prostate cancer cells. Prostate 26:260-269
13. Reyes-Moreno C, Koutsilieris M (1997) Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clin Exp Metastasis 15:205-217
14. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate can-cer: updated survival in the TAX 327 study. J Clin Oncol 26:242-245
15. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M (2007) A contemporary prog-nostic nomogram for men with hormone-refractory meta-static prostate cancer: a TAX327 study analysis. Clin Cancer Res 13:6396-6403
16. Smaletz O, Scher HI, Small EJ et al (2002) Nomogram for overall survival of patientswith progressivemetastatic prostate cancer after castration. J Clin Oncol 20:3972-3982
17. Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model for predicting survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol 21: 1232-1237